Maria Javier Ramirez

List of Publications by Year
in descending order

114 papers	6,586 citations	44069 48 h-index	66911 78 g-index
117 all docs	117 docs citations	117 times ranked	9633 citing authors

#	Article	IF	Citations
1	Dysbiosis and Alzheimerâ€™s Disease: Cause or Treatment Opportunity?. Cellular and Molecular Neurobiology, 2022, 42, 377-387.	3.3	24
2	p27, The Cell Cycle and AlzheimerÂ´s Disease. International Journal of Molecular Sciences, 2022, 23, 1211.	4.1	15
3	Brain Metabolic Alterations in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 3785.	4.1	28
4	Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model. Mechanisms of Ageing and Development, 2022, 204, 111668.	4.6	16
5	Biomarcadores en la enfermedad de Alzheimer. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 39-50.	0.2	2
6	Linking dietary methyl donors, maternal separation, and depression. , 2021, , 473-483.		0
7	Corticosteroid-binding-globulin (CBG)-deficient mice show high pY216-GSK3Î² and phosphorylated-Tau levels in the hippocampus. PLoS ONE, 2021, 16, e0246930.	2.5	2
8	Expression of Endothelial NOX5 Alters the Integrity of the Blood-Brain Barrier and Causes Loss of Memory in Aging Mice. Antioxidants, 2021, 10, 1311.	5.1	11
9	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	3.8	12
10	Biomarkers in Alzheimerâ€™s disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 27-37.	0.2	13
11	GLUT12 Expression in Brain of Mouse Models of Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 798-805.	4.0	14
12	Brain ventricular enlargement in human and murine acute intermittent porphyria. Human Molecular Genetics, 2020, 29, 3211-3223.	2.9	3
13	DHA Selectively Protects SAMP-8-Associated Cognitive Deficits Through Inhibition of JNK. Molecular Neurobiology, 2019, 56, 1618-1627.	4.0	13
14	Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration. Molecular Neurobiology, 2018, 55, 9328-9333.	4.0	1
15	Adrenomedullin, a Novel Target for Neurodegenerative Diseases. Molecular Neurobiology, 2018, 55, 8799-8814.	4.0	17
16	Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. International Journal of Pharmaceutics, 2018, 543, 245-256.	5.2	11
17	Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients, 2018, 10, 1398.	4.1	403
18	Interactions Between Age, Diet, and Insulin and Their Effect on Cognition. , 2018, , 223-238.		0

#	Article	IF	Citations
19	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 5177-5183.	4.0	21
20	Reduced serotonin levels after a lifestyle intervention in obese children: association with glucose and anthropometric measurements. Nutricion Hospitalaria, 2018, 35, 279-285.	0.3	5
21	Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 991-1001.	3.8	69
22	Effects of perinatal diet and prenatal stress on the behavioural profile of aged male and female rats. Journal of Psychopharmacology, 2017, 31, 356-364.	4.0	13
23	Serotonin 5-HT6 Receptor Antagonists in Alzheimerâ€™s Disease: Therapeutic Rationale and Current Development Status. CNS Drugs, 2017, 31, 19-32.	5.9	82
24	Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimerâ€™s disease. International Journal of Pharmaceutics, 2017, 517, 50-57.	5.2	106
25	GPR55: A therapeutic target for Parkinson's disease?. Neuropharmacology, 2017, 125, 319-332.	4.1	67
26	Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Current Opinion in Pharmacology, 2017, 37, 87-92.	3.5	119
27	Nutrition for the ageing brain: Towards evidence for an optimal diet. Ageing Research Reviews, 2017, 35, 222-240.	10.9	161
28	Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets. Frontiers in Pharmacology, 2017, 8, 280.	3.5	169
29	Adrenomedullin Contributes to Age-Related Memory Loss in Mice and Is Elevated in Aging Human Brains. Frontiers in Molecular Neuroscience, 2017, 10, 384.	2.9	21
30	An Increase in Plasma Homovanillic Acid with Cocoa Extract Consumption Is Associated with the Alleviation of Depressive Symptoms in Overweight or Obese Adults on an Energy Restricted Diet in a Randomized Controlled Trial. Journal of Nutrition, 2016, 146, 897S-904S.	2.9	23
31	Downâ€regulation of glutamatergic terminals (VGLUT1) driven by AÎ² in Alzheimer's disease. Hippocampus, 2016, 26, 1303-1312.	1.9	32
32	JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 963-967.	2.6	3
33	Purported Interactions of Amyloid-Î² andÂGlucocorticoids in Cytotoxicity andÂGenotoxicity: Implications inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 1085-1094.	2.6	2
34	Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches. Trends in Pharmacological Sciences, 2016, 37, 575-593.	8.7	36
35	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2016, 57, 94-105.	4.1	51
36	Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 511-517.	3.8	20

#	Article	IF	Citations
37	Methyl donor supplementation in rats reverses the deleterious effect of maternal separation on depression-like behaviour. Behavioural Brain Research, 2016, 299, 51-58.	2.2	54
38	Object recognition test for studying cognitive impairments in animal models of Alzheimer s disease. Frontiers in Bioscience - Scholar, 2015, 7, 10-29.	2.1	34
39	Decreased levels of guanosine 3â€², 5â€²â€monophosphate (c<scp>GMP</scp>) in cerebrospinal fluid (<scp>CSF</scp>) are associated with cognitive decline and amyloid pathology in <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2015, 41, 471-482.	3.2	84
40	Venlafaxine reverses decreased proliferation in the subventricular zone in a rat model of early life stress. Behavioural Brain Research, 2015, 292, 79-82.	2.2	4
41	Alterations in brain leptin signalling in spite of unchanged <scp>CSF</scp> leptin levels in Alzheimer's disease. Aging Cell, 2015, 14, 122-129.	6.7	56
42	c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2015, 6, 321.	3.5	284
43	Treatment Options in AlzheimerÂ´s Disease: The GABA Story. Current Pharmaceutical Design, 2015, 21, 4960-4971.	1.9	103
44	Revealing the cerebral regions and networks mediating vulnerability to depression: Oxidative metabolism mapping of rat brain. Behavioural Brain Research, 2014, 267, 83-94.	2.2	23
45	Serotonergic Therapies for Cognitive Symptoms in Alzheimerâ€™s Disease: Rationale and Current Status. Drugs, 2014, 74, 729-736.	10.9	77
46	Decreased rabphilin 3A immunoreactivity in Alzheimerâ€™s disease is associated with AÎ² burden. Neurochemistry International, 2014, 64, 29-36.	3.8	41
47	Effect of dietary restriction on peripheral monoamines and anxiety symptoms in obese subjects with metabolic syndrome. Psychoneuroendocrinology, 2014, 47, 98-106.	2.7	16
48	Expression of the Glucose Transporter GLUT12 in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2014, 42, 97-101.	2.6	15
49	Early cognitive stimulation compensates for memory and pathological changes in Tg2576 mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 837-847.	3.8	23
50	5-HT6 receptors and Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 15.	6.2	82
51	Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. International Journal of Neuropsychopharmacology, 2013, 16, 2245-2257.	2.1	52
52	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 2013, 34, 805-808.	3.1	152
53	Propranolol reduces cognitive deficits, amyloid Î² levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. International Journal of Neuropsychopharmacology, 2013, 16, 1351-1360.	2.1	23
54	Stress contributes to the development of central insulin resistance during aging: Implications for Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2332-2339.	3.8	35

#	Article	IF	Citations
55	Maternal deprivation effects on brain plasticity and recognition memory in adolescent male and female rats. Neuropharmacology, 2013, 68, 223-231.	4.1	103
56	Regulation of serotonin (5-HT) function by a VGLUT1 dependent glutamate pathway. Neuropharmacology, 2013, 70, 190-199.	4.1	7
57	Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology, 2013, 64, 137-144.	4.1	52
58	Mineralocorticoid Receptor Activation Induces Insulin Resistance Through câ€Jun Nâ€terminal kinases in Response to Chronic Corticosterone: Cognitive Implications. Journal of Neuroendocrinology, 2013, 25, 350-356.	2.6	23
59	Effects of Early Maternal Separation on Biobehavioral and Neuropathological Markers of Alzheimer's Disease in Adult Male Rats. Current Alzheimer Research, 2013, 10, 420-432.	1.4	48
60	Mechanisms Involved in BACE Upregulation Associated to Stress. Current Alzheimer Research, 2012, 9, 822-829.	1.4	13
61	Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. Neuropharmacology, 2012, 62, 1944-1953.	4.1	103
62	Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice. Neurobiology of Disease, 2012, 48, 439-446.	4.4	29
63	Postnatal maternal separation modifies the response to an obesogenic diet in adulthood. DMM Disease Models and Mechanisms, 2012, 5, 691-7.	2.4	34
64	Stressâ€induced anhedonia is associated with an increase in Alzheimer's diseaseâ€related markers. British Journal of Pharmacology, 2012, 165, 897-907.	5.4	54
65	Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus, 2011, 21, 999-1009.	1.9	46
66	Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action. Journal of Medicinal Chemistry, 2011, 54, 3086-3090.	6.4	85
67	5-HT6 receptor and cognition. Current Opinion in Pharmacology, 2011, 11, 94-100.	3.5	118
68	Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. European Neuropsychopharmacology, 2011, 21, 23-32.	0.7	55
69	Long Term Sex-Dependent Psychoneuroendocrine Effects of Maternal Deprivation and Juvenile Unpredictable Stress in Rats. Journal of Neuroendocrinology, 2011, 23, 329-344.	2.6	84
70	Sustained stress-induced changes in mice as a model for chronic depression. Psychopharmacology, 2010, 210, 393-406.	3.1	92
71	Regulation of markers of synaptic function in mouse models of depression: chronic mild stress and decreased expression of VGLUT1. Journal of Neurochemistry, 2010, 114, 1302-1314.	3.9	69
72	Insulin Levels are Decreased in the Cerebrospinal Fluid of Women with Prodomal Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 405-413.	2.6	68

#	Article	IF	Citations
73	Interactions Between Age, Stress and Insulin on Cognition: Implications for Alzheimer's Disease. Neuropsychopharmacology, 2010, 35, 1664-1673.	5.4	109
74	HPA Axis Dysregulation Associated to Apolipoprotein E4 Genotype in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 829-838.	2.6	73
75	5-HT6 Receptor Signal Transduction. International Review of Neurobiology, 2010, 94, 89-110.	2.0	13
76	Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. International Journal of Neuropsychopharmacology, 2010, 13, 775-784.	2.1	26
77	Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology, 2010, 59, 221-229.	4.1	94
78	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	2.6	38
79	Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: Involvement of the HPA axis. Psychoneuroendocrinology, 2009, 34, 1495-1505.	2.7	66
80	Effects of neonatal stress on markers of synaptic plasticity in the hippocampus: Implications for spatial memory. Hippocampus, 2009, 19, 1222-1231.	1.9	156
81	Effects of chronic blockade of 5â€HT₆ receptors on NMDA receptor subunits expression. Synapse, 2009, 63, 814-816.	1.2	3
82	Increased Vulnerability to Depressive-Like Behavior of Mice with Decreased Expression of VGLUT1. Biological Psychiatry, 2009, 66, 275-282.	1.3	118
83	S.27.03 Decreased VGLUT1 levels and long-term chronic mild stress: animal models addressing specific aspects of major depression. European Neuropsychopharmacology, 2009, 19, S214-S215.	0.7	0
84	P.2.b.012 Long-term neurobiological changes by chronic mild stress and residual alterations after antidepressant discontinuation. European Neuropsychopharmacology, 2009, 19, S397-S398.	0.7	0
85	Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology, 2008, 199, 1-14.	3.1	160
86	Effects of 5â€HT₆ receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. British Journal of Pharmacology, 2008, 155, 434-440.	5.4	71
87	Effects of maternal separation on hypothalamicâ€“pituitaryâ€“adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience, 2008, 154, 1218-1226.	2.3	164
88	Functional interaction between 5-HT6 receptors and hypothalamicâ€“pituitaryâ€“adrenal axis: Cognitive implications. Neuropharmacology, 2008, 54, 708-714.	4.1	29
89	Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 43-50.	2.6	39
90	Increase of locomotor activity underlying the behavioral disinhibition in Tg2576 mice.. Behavioral Neuroscience, 2007, 121, 340-344.	1.2	64

#	Article	IF	Citations
91	Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology, 2007, 32, 256-266.	2.7	445
92	Increased sensitivity to MPTP in human Î±-synuclein A30P transgenic mice. Neurobiology of Aging, 2006, 27, 848-856.	3.1	88
93	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1110-1117.	3.1	56
94	Effect of Selective Cholinergic Denervation on the Serotonergic System: Implications for Learning and Memory. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1074-1081.	1.7	35
95	Lack of localization of 5-HT6receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6receptor-mediated acetylcholine release. European Journal of Neuroscience, 2006, 24, 1299-1306.	2.6	110
96	Selective effects of the APOE Îµ4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiology of Disease, 2006, 22, 555-561.	4.4	26
97	Cholinergicâ€“serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimerâ€™s disease. Neuropsychologia, 2005, 43, 442-449.	1.6	193
98	Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease. Current Psychiatry Reviews, 2005, 1, 337-343.	0.9	6
99	Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neuroscience Letters, 2005, 375, 37-41.	2.1	64
100	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. Neuropsychopharmacology, 2004, 29, 410-416.	5.4	128
101	Changes in hippocampal SNAP-25 expression following afferent lesions. Brain Research, 2004, 997, 133-135.	2.2	8
102	Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology, 2004, 47, 225-232.	4.1	17
103	Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats. Psychopharmacology, 2003, 169, 35-41.	3.1	24
104	Adrenomedullin expression and function in the rat carotid body. Journal of Endocrinology, 2003, 176, 95-102.	2.6	14
105	GABAA receptor antagonists enhance cortical acetylcholine release induced by 5-HT3 receptor blockade in freely moving rats. Brain Research, 2002, 956, 81-85.	2.2	34
106	Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions. Journal of Neural Transmission, 2001, 108, 809-826.	2.8	11
107	Expression of Amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deafferentation lesions. Brain Research, 2001, 907, 222-232.	2.2	19
108	Î±-Lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. NeuroReport, 1999, 10, 3675-3680.	1.2	86

#	Article	IF	Citations
109	Differential interaction between 5-HT3 receptors and GABAergic neurons inhibiting acetylcholine release in rat entorhinal cortex slices. Brain Research, 1998, 801, 228-232.	2.2	26
110	Current Neurotransmitter Strategies in AD Drug Development. Advances in Behavioral Biology, 1998, , 851-859.	0.2	1
111	5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Brain Research, 1997, 757, 17-23.	2.2	29
112	Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex. Brain Research, 1996, 712, 274-280.	2.2	64
113	Involvement of neurokinins in the nonâ€cholinergic response to activation of 5â€HT₃ and 5â€HT₄ receptors in guineaâ€pig ileum. British Journal of Pharmacology, 1994, 111, 419-424.	5.4	44
114	On the nature of the 5â€HT receptor subtype inhibiting acetylcholine release in the guineaâ€pig ileum. British Journal of Pharmacology, 1994, 113, 77-80.	5.4	8